Immune Pharmaceuticals, Inc. (IMNP) managed to rebound with the stock declining -3.2% or $-0.01 to close the day at $0.18 on light trading volume of 3M shares, compared to its three month average trading volume of 5.73M. The New York New York 10016 based company has been underperforming the drug manufacturers – major group over the past 52 weeks, with the stock losing -70.73%, compared to the industry which has advanced 12.52% over the same period. With RSI of 43.63, the stock should still continue to rise and get closer to its one year target estimate of $3, making it a hold for now.
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The companys lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn’s disease. It is also developing NanoCyclo, a topical nanocapsule formulation of cyclosporine, for the treatment of psoriasis and atopic dermatitis; Ceplene, a small molecule, which has completed Phase III clinical trials targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies; Azixa, a Phase II clinical trial novel microtubular destabilizer that functions as a vascular disruption agent; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is in Phase II clinical trials for the treatment of patients with solid tumors. The companys products also include NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; novel technology platform for the construction of bispecific antibodies for immunotherapies; and AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies. It has license, and other collaborative research and development arrangements with BioNanoSim Ltd.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; Atlante Biotech SAS; Shire Biochem, Inc.; Lonza Sales AG; MabLife SAS; iCo Therapeutics Inc.; Dalhousie University; and Endo Pharmaceuticals Inc. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in New York, New York.
Ocwen Financial Corporation (OCN) grew with the stock adding 0.69% or $0.04 to close at $5.84 on active trading volume of 2.97M compared its three months average trading volume of 2.7M. The West Palm Beach Florida 33409 based company operating under the Mortgage Investment industry has been trending up for the last 52 weeks, with the shares price now 8.35% up for the period and up by 8.35% so far this year. With price target of $4.5 and a 352.71% rebound from 52-week low, Ocwen Financial Corporation has plenty of upside potential, making it a hold with a view buy.
Ocwen Financial Corporation, a financial services holding company, engages in servicing and origination of mortgage loans in the United States. Its Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset management services to owners of mortgage loans and foreclosed real estate. This segments residential servicing portfolio includes conventional, government insured, and non-agency loans. The companys Lending segment originates and purchases conventional and government-insured residential forward and reverse mortgage loans primarily through its correspondent lending arrangements, broker relationships, and directly with mortgage customers. Ocwen Financial Corporation was founded in 1988 and is headquartered in West Palm Beach, Florida.
Glu Mobile Inc. (GLUU) managed to rebound with the stock climbing 0.47% or $0.01 to close the day at $2.12 on lower than average trading volume of 2.93M shares, compared to its three month average trading volume of 3.19M. The San Francisco California 94105 based company has been outperforming the multimedia & graphics software companies by 8.0388% for last three months and its recent gains have pushed the stock slightly up 9.28% YTD, versus the multimedia & graphics software industry which is up 16.91% for the same period. The RSI of 40.4 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Glu Mobile Inc. develops, publishes, and markets a portfolio of games for the smartphones and tablet devices users. The company offers free-to-play action, celebrity, sports, and simulation genre mobile games. It creates games based on its own brands, including Contract Killer, Cooking Dash, Deer Hunter, Diner Dash, Eternity Warriors, Frontline Commando, Gun Bros, Heroes of Destiny, Racing Rivals, Tap Sports Baseball, and Tap Sports Football. The company also creates games based on third-party licensed brands, such as Kim Kardashian: Hollywood, Kendall and Kylie, Katy Perry Pop, James Bond: World of Espionage, Mission Impossible: Rogue Nation, and Sniper X With Jason Statham. Glu Mobile Inc. markets, sells, and distributes its games primarily through direct-to-consumer digital storefronts worldwide. The company was formerly known as Sorrent, Inc. and changed its name to Glu Mobile Inc. in May 2005. Glu Mobile Inc. was incorporated in 2001 and is headquartered in San Francisco, California.